Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

NCT03013946 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT03013946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03013946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 3
Overall status
Terminated
Start date
January 18, 2017
Completion date
January 16, 2024
Enrollment
121 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell cancer, recurrent, renal cell carcinoma, metastatic